Zonisamide in the treatment of epilepsy

Bibliography

• About Epilepsy. Epilepsy Foundation. 2010. Available from: www.epilepsyfoundation.org [Last accessed 19 September 2011]
   Google Scholar
• Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy in the United States. Epilepsia 2009;12:2186-91
   Google Scholar
• Masuda Y, Utsui Y, Shiraishi Y, Pharmacokinetic and phearmacodynamic tolerance of a new anticonvulsant agent (3-sulfamoylmethyl-1,2-benzisoxazole) compared to phenobarbital, diphenylhydantoin and carbamazepine in rats. Arch Int Pharmacodyn Ther 1979;240:79-89
   PubMedGoogle Scholar
• Seino M. Review of zonisamide development in Japan. Seizure 2004;Suppl 1:S2-4
   Google Scholar
• Kamei C, Oka M, Masuda Y, Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats. Arch Int Pharmacodyn Ther 1981;249:164-76
   PubMedGoogle Scholar
• Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia 1986;27:367-74
   PubMedGoogle Scholar
• Wada Y, Hasegawa H, Yamaguchi N. Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912), in an experimental model of photosensitive epilepsy. Epilepsy Res 1990;7:117-20
   PubMedGoogle Scholar
• Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30:230-40
   PubMed Web of Science ®Google Scholar
• Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-8
   PubMed Web of Science ®Google Scholar
• Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989;3:138-43
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kawakami K, Nishimura S, Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7
   PubMed Web of Science ®Google Scholar
• Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5:115-19
   PubMed Web of Science ®Google Scholar
• Matar N, Jin W, Wrubel H, Zonisamide block of cloned human T-type voltage-gated calcium channels. Epilepsy Res 2009;83:224-34
   PubMed Web of Science ®Google Scholar
• Kawai M, Hiramatsu M, Endo A, Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from hippocampal slices of E1 mice. Neurosciences 1994;20:115-19
   Google Scholar
• Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116:1-6
   PubMedGoogle Scholar
• Okada M, Kawata Y, Mizuno K, Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998;124:1277-85
   PubMed Web of Science ®Google Scholar
• Huang CW, Huang CC, Wu SN. Activation by zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells. J Pharmacol Exp Ther 2007;321:98-106
   PubMed Web of Science ®Google Scholar
• Masuda Y, Noguchi H, Karasawa T. Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects. Arzneimittelforschung 1994;44:267-9
   PubMedGoogle Scholar
• Thone J, Leniger T, Splettstosser F, Wiemann M. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 2008;79:105-11
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Odani A, Tanigawara Y, Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull 1994;17:323-6
   PubMed Web of Science ®Google Scholar
• Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993;45:760-87
   PubMed Web of Science ®Google Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;Suppl 1:S5-9
   Google Scholar
• Nakasa H, Nakamura H, Ono S, Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol 1998;54:177-83
   PubMed Web of Science ®Google Scholar
• Okada Y, Seo T, Ishitsu T, Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Ther Drug Monit 2008;30:540-3
   PubMed Web of Science ®Google Scholar
• Stiff DD, Robicheau JT, Zemaitis MA. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica 1992;22:1-11
   PubMed Web of Science ®Google Scholar
• Nakasa H, Komiya M, Ohmori S, Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 1993;44:216-21
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Bergen D, Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res 2004;62:1-11
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Brodie M, Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet 2005;44:517-23
   PubMedGoogle Scholar
• Levy RH, Ragueneau-Majlessi I, Brodie MJ, Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit 2005;27:193-8
   PubMed Web of Science ®Google Scholar
• Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther 2004;26:2056-65
   PubMed Web of Science ®Google Scholar
• Schmidt D, Jacob R, Loiseau P, Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73
   PubMed Web of Science ®Google Scholar
• Faught E, Ayala R, Montouris GG, Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-9
   PubMed Web of Science ®Google Scholar
• Sackellares JC, Ramsay RE, Wilder BJ, Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-17
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Duncan R, Vespignani H, Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:31-41
   Web of Science ®Google Scholar
• Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2005;19:CD001416
   Google Scholar
• Leppik IE, Willmore LJ, Homan RW, Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165-73
   PubMed Web of Science ®Google Scholar
• Dupont S, Striano S, Trinka E, Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand 2010;121:141-8
   PubMed Web of Science ®Google Scholar
• Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;Suppl 1:S26-32
   Google Scholar
• Coppola G, Grosso S, Verrotti A, Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res 2009;83:112-16
   PubMed Web of Science ®Google Scholar
• Eun SH, Kim HD, Eun BL, Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure 2011; [Epub ahead of print]
   PubMedGoogle Scholar
• Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999;21:157-61
   PubMed Web of Science ®Google Scholar
• Suzuki Y. Zonisamide in West syndrome. Brain Dev 2001;23:658-61
   PubMed Web of Science ®Google Scholar
• Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004;62:296-8
   PubMed Web of Science ®Google Scholar
• Yum MS, Ko TS. Zonisamide in West syndrome: an open label study. Epileptic Disord 2009;11:339-44
   PubMed Web of Science ®Google Scholar
• Yagi K, Seino M. Methodologic requirements for clinical trials in refractory epilepsies – our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:79-85
   PubMed Web of Science ®Google Scholar
• Kotani H, Hirai K, Nishiki T, Zonisamide monotherapy against absence attacks: report of two cases. No To Hattatsu 1994;26:349-54
   PubMedGoogle Scholar
• Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. Seizure 2004(Suppl 1):S34-9
   Google Scholar
• Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005;64:31-4
   PubMed Web of Science ®Google Scholar
• Marinas A, Villanueva V, Giraldez BG, Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009;11:61-6
   PubMed Web of Science ®Google Scholar
• Kothare SV, Valencia I, Khurana DS, Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6:267-70
   PubMed Web of Science ®Google Scholar
• Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38:928-31
   PubMed Web of Science ®Google Scholar
• Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observation in seven patients. Epilepsy Res 1998;29:109-14
   PubMed Web of Science ®Google Scholar
• Vossler DG, Conry JA, Murphy JV, Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10:31-4
   PubMed Web of Science ®Google Scholar
• Berent S, Sackellares JC, Giordani B, Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987;28:61-7
   PubMed Web of Science ®Google Scholar
• White JR, Walczak TS, Marino SE, Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010;75:513-18
   PubMed Web of Science ®Google Scholar
• Michael CT, Starr JL. Psychosis following initiation of zonisamide. Am J Psychiatry 2007;164:682
   PubMed Web of Science ®Google Scholar
• Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 2003;28:184-9
   PubMed Web of Science ®Google Scholar
• Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008;144:232-5
   PubMed Web of Science ®Google Scholar